27.04.2017
- Bristol-Myers Squibb has announced another collaboration to use Opdivo in a combination cancer treatment, this time working with French biotech Transgene. The potential new therapy...
24.01.2017
- US drugmaker Merck has settled its patent dispute with rival Bristol-Myers Squibb (BMS) and Japan’s Ono Pharmaceutical over cancer immunotherapy Keytruda. Under terms of the...
12.10.2016
- The newly developed Bristol-Myers (BMS) lung cancer drug Opdivo, a so-called checkpoint inhibitor that stimulates the immune system so that it can attack malignant tumours, has...
06.06.2016
- The European Commission has granted approval for Novartis’ Afinitor (everolimus) for treating unresectable or metastatic, well-differentiated non-functional neuroendocrine tumors...
24.05.2016
- The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s (BMS) cancer drug, Opdivo, to treat classical Hodgkin Lymphoma (HL). The approval is the eighth for...
27.04.2016
- US regulators have given a breakthrough designation to Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) for treating head and neck cancer. This is the fifth breakthrough...
14.04.2016
- Bristol-Myers Squibb’s cancer drug Opdivo can now be used to treat more patients with lung cancer or kidney cancer after European regulators expanded its indications. The EU...
04.04.2016
- Analysts love looking into the future, particularly when it comes to big pharma’s prospect for growth and earnings. The industry experts of Morningstar see slowing patent losses...
